High-dose etoposide (2 g/m 2 ) plus G-CSF is a very effective regimen for peripheral blood progenitor cell (PBPC) mobilization. Unfortunately, neutropenia is common. The infectious complications associated with high-dose etoposide have not been previously described. After noting a high incidence of hospitalizations for neutropenic fever, we began a vigorous prophylactic antibiotic regimen for patients receiving high-dose etoposide plus G-CSF, attempting to reduce infectious complications. Ninety-eight patients underwent etoposide mobilization between December 1997 and June 2000. Three chronological patient groups received: (1) no specific antibiotic prophylaxis (n = 44); (2) vancomycin i.v., cefepime i.v., clarithromycin p.o., and ciprofloxacin p.o. (n = 27); and (3) vancomycin i.v., clarithromycin p.o., and ciprofloxacin p.o. (n = 27). The patients not receiving antibiotic prophylaxis had a 68% incidence of hospitalization for neutropenic fever. In the patients receiving prophylaxis, the incidence was reduced to 26% and 15% respectively, for an overall incidence of 20% (P Ͻ 0.001 for comparison between prophylaxed and unprophylaxed groups). We conclude that etoposide mobilization is associated with a significant incidence of neutropenic fever, which can be substantially reduced by a vigorous antimicrobial prophylactic program.
Peripheral blood progenitor cell (PBPC) mobilization is a crucial preparatory step in autologous PBPC transplantation, and retrieval of an adequate quantity of PBPC is essential to successful transplant. 1 Although G-CSF is effective in mobilizing CD34
+ cells, it has recently been recognized that high-dose etoposide plus G-CSF may be more effective to generate large numbers of CD34 + cells, either as a primary mobilization strategy or as salvage for those who fail other mobilization regimens. [2] [3] [4] [5] [6] In 1997, this center began to utilize etoposide plus G-CSF for mobilization, but noted a high rate of hospital admission for neutropenic fever in this group. Therefore, a vigorous quadruple regimen of vancomycin, cefepime, clarithromycin and ciprofloxacin was instituted. The cefepime was subsequently omitted with equally good results from the triple antibiotic combination.
Study design
All 98 patients undergoing autologous PBPC transplantation with etoposide/G-CSF mobilization between December 1997 and June 2000 had their medical records, microbiologic data, and stem cell yields reviewed. The dose of etoposide was 2 g/m 2 , given as a continuous intravenous infusion over 24 h, and the dose of G-CSF was 10 g/kg/day, daily. All patients developed neutropenia, and PBPC collection began when the peripheral WBC reached 1000/mm 3 . All patients had triple-lumen Horizon catheters placed before mobilization.
Between December 1997 and May 1999, 44 patients underwent etoposide mobilization without a specific antimicrobial prophylaxis program. Between June 1999 and January 2000, patients received quadruple prophylaxis as follows: vancomycin 1 g i.v. every day, cefepime 1 g i.v. every day, clarithromycin 250 mg p.o. twice a day, and ciprofloxacin 500 mg p.o. twice a day (n = 27). This was started after the dose of etoposide and continued until the patient was no longer neutropenic and pheresis had been completed. Between January 2000 and June 2000, cefepime was omitted from the above regimen; thus patients received vancomycin, clarithromycin, and ciprofloxacin at the above doses (n = 27). Demographics of these three patient groups are found in Table 1 , as well as courses of prior chemotherapy and radiation therapy. The major endpoint was hospitalization for neutropenic fever. Secondary endpoints were specific bacterial and fungal infections, CD34
+ yield, and duration of neutropenia. All patients with neutropenic fever were hospitalized and treated with broad-spectrum antimicrobial therapy according to published guidelines.
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Results Table 1 shows that the antibiotic-prophylaxed and non-prophylaxed groups did not differ significantly in terms of age, gender, diagnosis, and courses of prior radiation therapy. Prophylaxed patients were significantly more likely to have had at least two prior courses of chemotherapy, and a higher percentage of non-prophylaxed patients were undergoing etoposide/G-CSF priming as salvage mobilization rather than primary mobilization, as compared with prophylaxed patients. However, these two variables were subsequently included in a logistic regression model (Table  2) , and when the effect of antibiotic prophylaxis was tested, Table 2 Logistic regression model neither of these variables (number of courses of chemotherapy, and primary vs salvage etoposide/G-CSF mobilization) was found to be significant. By contrast, lack of antibiotic prophylaxis was a significant risk factor for neutropenic fever (P = 0.0007, Table 3 ). Hematologic effects of etoposide/G-CSF mobilization are shown in Table 4 . After receiving etoposide/G-CSF, all patients experienced absolute neutropenia of Ͻ500/mm 3 for a median of 6 days; the median onset of neutropenia was 7 days after receiving etoposide. Recovery of the WBC count to Ͼ1000/mm 3 occurred at a median of 14 days after the etoposide dose. No significant differences were seen between prophylaxed and unprophylaxed groups in the duration of neutropenia, the time of onset of neutropenia, the median time from etoposide administration to first pheresis, or the number of phereses required.
Etoposide plus G-CSF was employed as the initial mobilizing regimen, or was used for patients failing to collect 2.0 ϫ 10 6 CD34 cells/kg with G-CSF alone (salvage mobilization). The median yield of CD34 + cells with initial mobilization was 14.7 ϫ 10 6 cells/kg in the unprophylaxed and 13.3 ϫ 10 6 cells/kg in the prophylaxed groups, respectively, which was not significantly different (P = 0.97). The yield with salvage mobilization was 4.2 ϫ 10 6 cells/kg in the unprophylaxed and 5.6 ϫ 10 6 cells/kg in the prophylaxed group, which was also not significantly different (P = 0.85). The occurrence of neutropenic fever did not affect CD34 + cell yield. Neutropenic fever requiring admission (Tables 3 and 5 ) occurred in 28/44 (64.1%) of unprophylaxed patients, but only 11/54 (20%) of prophylaxed patients (P = Ͻ0.0001). In the prophylaxed groups, 7/27 (26%) receiving the quadruple regimen and 4/27 (15%) receiving the triple regimen developed neutropenic fever, which was not a significant difference between the two prophylaxed groups (P = 0.31).
The majority of patients with neutropenic fever did not have a documented source of infection. Positive blood cul- Table 6 Positive blood cultures and other infections in patients receiving etoposide/G-CSF mobilization
No prophylaxis Positive blood cultures (3)
Viridans streptococcus (1) Micrococcus ( (Table 6 ). However, there was a trend towards more total infections in the unprophylaxed group (7/44, or 16%) than in the prophylaxed group (3/54, or 6%) (P = 0.11), although some of these would not have been preventable by the antibacterial agents used (eg cutaneous herpes simplex infection).
Fungemia (Candida parapsilosis) occurred in one patient in the prophylaxed group (on quadruple therapy); Candida esophagitis occurred in one patient in the unprophylaxed group. No other invasive fungal infections were diagnosed in either group.
Discussion
The combination of high-dose etoposide and G-CSF has been proven to be an excellent method for collection of large quantities of CD34 + stem cells prior to autologous PBPC transplantation. However, this etoposide mobilization regimen is associated with a significant incidence of neutropenic fever, in that two-thirds of unprophylaxed patients required admission for this complication. Although specific infections were not diagnosed in most patients, and blood culture positivity rates were relatively low, this high rate of hospital admissions was highly problematic. In response to this, a quadruple regimen of antimicrobial prophylaxis was instituted with a striking reduction in the admission rate for neutropenic fever, from 64.1% to 20%. Omission of cefepime from the regimen did not diminish the effectiveness of this antimicrobial prophylaxis.
Limitations of this study included the fact that it was not a randomized trial. However, the marked difference in the number of admissions for neutropenic fever supports the use of such a combination antimicrobial regimen in patients undergoing etoposide mobilization, and highlights this patient population as being at particular risk of neutropenic fever when prophylaxis is not administered. The authors do not advocate such a vigorous regimen for all neutropenic patients. Indeed, current guidelines 7 do not support such broad antibiotic regimens for patients with neutropenia in general. The regimen presented here is actually more a preemptive therapy regimen than a prophylactic regimen per se. It is reasonable to ask whether a less broad-spectrum regimen might have been equally effective.
This broad-spectrum regimen raises some theoretical concerns, such as the potential to select out for resistant bacterial organisms or fungi. In fact, invasive fungal infection occurred in only one patient from each group (Candida parapsilosis fungemia in one patient in the prophylaxed group, and Candida esophagitis in one patient in the unprophylaxed group). Had the incidence of invasive fungal infections in the prophylaxed group been higher, some consideration would have been given to inclusion of systemic antifungal prophylaxis in some form. However, this has not proved to be necessary, likely due to the relatively short duration of neutropenia and thus of prophylaxis. Oral nystatin suspension would be a reasonable addition to this regimen. In the most recent prophylaxed group, those receiving triple therapy with the omission of cefepime, no invasive fungal infections occurred. For febrile neutropenic patients who were admitted to the hospital, systemic antifungal therapy was administered according to published guidelines for the timing of such therapy, as regards the duration of neutropenic fever. 7 Similarly, no infections with vancomycin-resistant enterococci (VRE) or multi-resistant Gram-negative bacilli occurred in any of the groups during the stem-cell mobilization phase. Thus, the broad-spectrum prophylactic regimen utilized here did not appear to have significant adverse effects in terms of selecting out for resistant organisms.
In conclusion, mobilization of CD34 + cells with highdose etoposide and G-CSF is a highly effective regimen in preparation for autologous PBPC transplant, but is associated with significant neutropenia. The high rate of neutropenic fever admissions seen in the initial patient group was drastically reduced when a broad-spectrum antimicrobial prophylaxis regimen was instituted. This regimen was well tolerated and did not appear to predispose patients to developing infections with more resistant organisms. A regimen of intravenous vancomycin plus oral ciprofloxacin and clarithromycin appears to be safe and effective in preventing neutropenic fever before autologous PBPC transplant, and thus helps to maintain the outpatient localization of the stem cell mobilization phase. Whether a less broadspectrum antibiotic regimen would have had similar effects is a question for future investigation.
